Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Intermap Announces $1 Million Program in Malaysia and Business Updates
-
Hydreight Partners with American Frontline Nurses with a Network of Over 26,000 Nurses
-
SIGA Names Larry Miller General Counsel
-
Coherent Announces Optical Circuit Switch for Data Centers
-
Bombardier’s Global 7500 Jet Sets More Than 30 Speed Records, as Precedent-Setting Program Operates Flawlessly Around the World
-
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases
-
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
-
ProfitRocket AI Announces Relaunch, Presale, and Airdrop Following An Epic Overhaul
-
Form 8.3 - [abrdn EUROPEAN LOGISTICS INCOME PLC] - 22 03 2024 - (CGWL)
-
At the Yacht Club de Monaco yachts become ‘smarter’
-
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
-
Rabbi Marvin Hier, Founder and Dean Emeritus of the Simon Wiesenthal Center and Museum of Tolerance, Issues Statement Regarding Nelson Peltz
-
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
-
Western Metallica Provides Update on Planned Drilling Program at the Caña Brava Project
-
Regeneron Provides Update on Biologics License Application for Odronextamab
-
ThreeD Capital Inc. Announces New YouTube Channel
-
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
-
Agriculture Supply Chain Enterprise Technology Leader Regrow Earns B Corp Certification
-
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
-
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
-
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and O
-
Bitfarms Announces CEO Transition
-
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
-
ADM Endeavors Receives Final Building Permits for New Texas Facility
-
Constellium Ravenswood selected by US Department of Energy to receive $75 million investment to deploy low to zero carbon technology
-
Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership
-
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
-
Cronos Launches Lord Jones® Chocolate Fusions
-
OTC Markets Group Welcomes Netcompany Group AS to OTCQX
-
Aligning Missions, Getting Hired Now Powered by CareerCircle
-
Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone
-
MAG Silver Provides Notice of Updated Juanicipio Technical Report
-
Ring Energy Announces Participation in Water Tower Research Fireside Chat Event on March 26, 2024
-
Net Asset Value(s)
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Wincanton plc
-
Hepsiburada Announces Fourth Quarter and Full Year 2023 Financial Results
-
eGain Announces AssistGPT™ for CCaaS at Enterprise Connect
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
-
Animoca Brand’s Lost Club Toys Integrates Into The Binary Holding’s Ecosystem to Deliver Enhanced Infrastructure and User Engagement Capabilities for Telecom Partners
-
Transactions in connection with share buyback programme
-
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
-
Issue of Equity and Total Voting Rights and Capital
-
Issue of Equity and Total Voting Rights
-
Man Group PLC : Form 8.3 - Barratt Developments plc
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Irish Residential Properties REIT PLC
-
Man Group PLC : Form 8.3 - Tritax Big Box REIT plc
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Redrow plc - Ordinary Shares
-
Man Group PLC : Form 8.3 - Smith (DS) plc
